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ABSTRACT 
Background: Inconsistent fat-free mass (FFM) and muscle strength responses have been 
reported in randomized clinical trials (RCTs) administering testosterone replacement therapy 
(TRT) to middle-aged and elderly men.  Our objective was to conduct a meta-analysis to 
determine whether TRT improves FFM and muscle strength in middle-aged and elderly men, 
and whether the muscular responses vary by TRT administration route. 
Methods: Systematic literature searches of MEDLINE/PubMed and the Cochrane Library were 
conducted from inception through March 31st, 2017 to identify double-blind RCTs that compared 
intramuscular or transdermal TRT versus placebo and that reported assessments of FFM or 
upper- or lower-extremity strength.  Studies were identified and data were extracted and 
validated by three investigators, with disagreement resolved by consensus.  Using a random 
effects model, individual effect sizes (ESs) were determined from 31 RCTs reporting FFM 
(sample size: n=1213 TRT, n=1168 placebo), and 17 reporting upper- or lower-extremity 
strength (n=2572 TRT, n=2523 placebo).  Heterogeneity was examined and sensitivity analyses 
were performed. 
Results: When administration routes were collectively assessed, TRT was associated with 
increases in FFM [ES=1.20±0.15 (95%CI: 0.91, 1.49)], total body strength [ES=0.90±0.12 
(0.67, 1.14)], lower-extremity strength [ES=0.77±0.16 (0.45, 1.08)], and upper-extremity 
strength [ES=1.13±0.18 (0.78, 1.47)] (P<0.001 for all).  When administration routes were 
evaluated separately, the ES magnitudes were larger and the percent changes were 3-5 times 
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greater for intramuscular TRT than for transdermal formulations versus respective placebos, for 
all outcomes evaluated.  Specifically, intramuscular TRT was associated with a 5.7% increase in 
FFM [ES=1.49±0.18 (1.13, 1.84)] and 10-13% increases in total body strength [ES=1.39±0.12 
(1.15, 1.63)], lower-extremity strength [ES=1.39±0.17 (1.07, 1.72)], and upper-extremity 
strength [ES=1.37±0.17 (1.03, 1.70)] (P<0.001 for all).  In comparison, transdermal TRT was 
associated with only a 1.7% increase in FFM [ES=0.98±0.21 (0.58, 1.39)] and only 2-5% 
increases in total body [ES=0.55±0.17 (0.22, 0.88)] and upper-extremity strength [ES=0.97±0.24 
(0.50, 1.45)] (P<0.001).  Interestingly, transdermal TRT produced no change in lower-extremity 
strength versus placebo [ES=0.26±0.23 (-0.19, 0.70), P=0.26].  Sub-analyses of RCTs limiting 
enrollment to men ≥60 years of age produced similar results. 
Conclusions: Intramuscular TRT is more effective than transdermal formulations at increasing 
LBM and improving muscle strength in middle-aged and elderly men, particularly in the lower-
extremities. 
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INTRODUCTION  
Serum testosterone declines by ~1.2% per year in middle-aged and older men [1].  Across 
the aging spectrum, hypogonadism (i.e., serum testosterone <300 ng/dL) is associated with 
deficits in muscle strength [2] and reduced fat-free mass (FFM) [3], along with a host of other 
health concerns [4].  These muscular deficits develop gradually and are particularly 
apparent in lower extremity muscle groups involved in locomotion and balance [5], 
suggesting impaired physical function accompanies hypogonadism.  Several meta-analyses 
indicate that testosterone replacement therapy (TRT) modestly increases FFM [6, 7] and 
produces small improvements in muscle strength in middle-aged and elderly men [8, 7].  
However, these relatively small muscular benefits remain an area of clinical debate, in terms of 
weighing the risk-to-benefit trade-off and their relevance to improved physical function [4, 9]. 
Despite the existing evidence, inconsistent FFM and muscle strength responses have 
been observed in double-blind, placebo-controlled randomized clinical trials (RCTs) 
administering TRT to middle-aged and elderly men [10].  For example, several RCTs have 
reported that transdermal patch- and gel-based TRT formulations produced small (0.9 – 1.9 kg) 
increases in FFM in elderly men, but did not improve muscle function in comparison with 
placebo [11, 12] or resulted in only minor improvements in muscle strength [13, 14].  In contrast, 
other RCTs indicate that elderly men exhibited relatively larger (3.1 – 4.2 kg) increases in FFM 
in response to intramuscular TRT, along with ~10-30% improvements in strength [15-17].  One 
explanation for these differing responses is that the musculoskeletal benefits of TRT may vary by 
route of administration (i.e., transdermal vs intramuscular) [10].  Indeed, transdermal and 
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intramuscular TRT administration routes provide different testosterone doses [9] and produce 
differing pharmacokinetics of androgen elevation [18, 19],  which may affect musculoskeletal 
outcomes.  For example, intramuscular TRT formulations produce supraphysiologic 
testosterone concentrations for several days following injection, with values gradually 
declining into the physiologic range thereafter [18, 20].  In comparison, transdermal TRT 
formulations produce less robust testosterone elevations [19] that more consistently remain 
within the physiologic range [18].  The primary objectives of this systematic review and meta-
analysis were to determine whether TRT improves FFM and muscle strength in middle-aged and 
elderly men, and whether the muscular responses to TRT vary by administration route.  We 
hypothesized that intramuscular TRT would produce a greater magnitude of improvement in 
both FFM and muscle strength than transdermal TRT, when compared with respective placebos, 
because 1) TRT produces dose-dependent muscular improvement in older men [21] and 2) 
intramuscular TRT elevates circulating testosterone to a greater magnitude than 
transdermal formulations [19, 18]. 
METHODS 
Data Sources and Searches 
 Our meta-analysis followed the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA).  Three authors systematically searched PubMed and the Cochrane 
Register through March 31st, 2017 using the following search strategy: (testosterone OR 
androgen) AND (men OR males) AND (clinical trial) AND (sarcopenia OR muscle OR lean 
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mass OR fat-free mass OR strength OR physical performance) and agreed upon eligibility of 
each study.  This strategy was supplemented by manual searches of bibliographies from 
identified studies.  Information from selected trials was extracted and verified in triplicate. 
Study Selection 
 Inclusion criteria were pre-defined and included: 1) publications in English language-
based refereed journals; 2) double-blind RCTs that compared participants receiving TRT versus 
placebo; 3) participant mean age of ≥45 years in the TRT and placebo groups; 4) TRT 
administration via intramuscular or transdermal (patch- or gel-based) formulations, with method 
and dose specified, for a minimum of 8 continuous weeks; 5) at least one of the following 
outcome measures reported: total body FFM, or upper-extremity or lower-extremity maximal 
strength; and 6) sufficient information to allow statistical comparisons among groups reported in 
the paper or provided by the corresponding authors during a supplemental query.  We excluded 
trials 1) where endogenous testosterone secretion was experimentally suppressed prior to 
initiation of TRT because these studies did not have a true placebo group, 2) that administered 
androgens other than testosterone, 3) that co-administered drugs which affect muscular outcomes 
or sex-steroid metabolism, unless treatment arms existed that received only TRT and placebo, 
and 4) where exercise was combined with TRT, unless there were clearly delineated groups 
receiving TRT and placebo without exercise.  A minimum duration of 8 continuous weeks was 
selected because FFM and strength improvements are observable within this time frame, but 
may not occur in studies of shorter duration.  We checked for study duplication based on 
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authorship, study description, number of participants, and participant characteristics, to ensure 
that we did not include more than one study reporting the same dataset.  When duplication 
occurred, we used the report containing the most comprehensive data for each outcome. 
Data Extraction and Quality Assessment 
 The primary outcomes were total body FFM and total body strength, which represented a 
combination of upper- and lower-extremity strength measures.  Secondary outcomes were upper- 
and lower-extremity strength.  Data were extracted by trial arm and were validated in triplicate.  
Reviewers used an established tool to evaluate the quality of each trial [22].  Authors were 
contacted twice by email to ask for additional information if a trial met inclusionary criteria, but 
did not report data in a manner that would allow statistical assessment with our a priori methods.  
Studies were excluded if useable data could not be obtained with the above method. 
Data Synthesis and Analysis 
 To account for differences in units of strength measures, we adopted the Hedge’s g-index 
[23] to characterize the effect size (ES) of each data point, as shown in the following equation, 
with small sample size correction: 
g =c(m) 
𝑦�𝑑− 𝑦�𝑐
𝑆𝑝𝑜𝑜𝑙𝑒𝑑
 
where 𝑦�𝑑 is the average change from baseline measurement of the drug group and 𝑦�𝑐 is the 
average change from baseline measurement of the control group. 𝑆𝑝𝑜𝑜𝑙𝑒𝑑 is the pooled within-
study standard deviation.  c(m) is a correction factor given as the following: c(m) = 1 - 
3
4𝑚−9
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where m = 𝑛𝑑 + 𝑛𝑝 with 𝑛𝑑 and 𝑛𝑝 being the sample sizes in the drug and placebo group at post 
treatment, respectively.  The converted ES and its variance for each study was included in the 
analysis.  Heterogeneity was assessed using the Q statistic [23].  Our analysis indicated that 
heterogeneity was significant (<0.05) in all scenarios considered.  Thus, a random effects model 
was fit using the DerSimonian-Laird approach to account for heterogeneity across studies [24].  
Improvement was calculated as:  𝑦�𝑑𝑏− 𝑦�𝑐𝑏
𝑦�𝑐𝑏
∗ 100% where 𝑦�𝑑𝑏 is the ratio between post treatment 
and pre-treatment measurements of drug group and 𝑦�𝑐𝑏 is the ratio between post treatment and 
pre-treatment measurements of placebo group.   
A g-index statistic was determined for total body FFM and for each muscle strength 
measure.  ESs were coded such that positive numbers reflected increasing FFM or strength and 
negative values reflected decreasing values in comparison to placebo.  For each dependent 
measure, an ES and the accompanying 95% confidence interval (CI) are reported.  ESs of 0.20-
0.49 were considered small, 0.50-0.79 medium, 0.80-1.1 large, and ≥1.2 very large [25]. 
 As noted above, several trials contained multiple upper- and/or lower-extremity strength 
measures.  To examine bias due to lack of independent data points, we conducted sensitivity 
analyses on total body strength, upper-extremity strength, and lower-extremity strength by 
combining studies with multiple data points together using the Mantel-Haenszel method [26].  
Specifically, we combined studies with multiple data points as one study, when measurement 
units were identical.  Sensitivity analysis was not performed for FFM because all data points 
represented individual groups and the units of measurement were consistent among all studies.  
This article is protected by copyright. All rights reserved.
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To assess whether an age effect existed, we also performed subgroup analyses on all eligible 
RCTs that reported FFM or muscle strength outcomes and limited enrollment to men ≥60 
years of age.  Analyses were conducted using the open source statistical software package 
“metaphor” (v3.1.0) [27]. 
RESULTS 
Study Selection and Characteristics  
 The initial search yielded 1227 publications, of which 127 were subjected to further 
scrutiny (Figure 1).  From the references of these papers we identified 10 additional publications 
that required further review.  Of these, 41 unique double-blind, placebo-controlled RCTs met our 
a priori selection criteria [28-31, 16, 32-37, 15, 38-40, 13, 41-48, 17, 49, 11, 50, 51, 14, 52-59, 
12, 60, 61].  All eligible studies were randomized, with investigators, providers, and 
subjects blinded to treatment allocation, and eligibility criteria were specified.  Other 
aspects associated with study quality assessment are reported in Table 1.  We included data 
from 34 of these studies in the primary analysis, of which 15 administered intramuscular TRT 
and 18 administered transdermal TRT, with study characteristics reported in Table 2.  In our 
subgroup analysis, we included data from 19 of the above-mentioned studies that limited 
enrollment to men ≥60 years of age, of which 9 administered intramuscular TRT [28, 31, 
16, 33, 35, 15, 17, 49, 53] and 10 administered transdermal TRT [38, 40, 13, 42, 44, 45, 11, 
50, 14, 55].  We were unable to include the additional 7 RCTs that met our selection criteria [56-
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59, 12, 60, 61] because data were not reported in the necessary format for our a priori statistical 
design and were not provided by authors upon query (Table 3).   
Fat-Free Mass  
We included 31 transdermal and intramuscular TRT studies (containing 34 ESs) that 
reported FFM (Figure 2) and obtained a pooled overall treatment ES of 1.20 (95%CI: 0.91-1.49; 
P<0.001), representing a 3.4% increase in FFM for TRT versus placebo (Table 4).  Secondary 
analysis of the 15 studies evaluating intramuscular TRT produced an ES of 1.49 (1.13, 1.84; 
P<0.001), representing a 5.7% FFM increase.  Conversely, analysis of 19 studies evaluating 
transdermal TRT produced an ES of 0.98 (0.58, 1.39; P<0.001), representing only a 1.7% 
increase in FFM.   
Total Body Strength 
 For total body strength, we integrated 17 transdermal and intramuscular TRT studies 
(containing 100 ESs) that reported lower-extremity (Figure 3) or upper-extremity (Figure 4) 
strength measures and obtained a pooled overall treatment ES of 0.90 (0.67, 1.14; P<0.001), 
representing a 6.1% increase in strength versus placebo (Table 4).  Separate analysis of the 9 
intramuscular TRT studies (containing 44 ESs) resulted in an ES of 1.39 (1.15, 1.63; P<0.001), 
representing an 11.2% strength improvement.  In comparison, analysis of the 8 transdermal TRT 
studies (containing 56 ESs) produced an ES of 0.55 (0.22, 0.88; P<0.001), representing only a 
2.1% strength increase.   
Lower Extremity Strength 
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 For lower-extremity strength, we integrated 17 transdermal and intramuscular TRT 
studies (containing 62 ESs) and obtained a pooled overall treatment ES of 0.77 (0.45, 1.08; 
P<0.001), representing a 5% strength increase versus placebo (Table 4).  Separate analysis of 9 
intramuscular studies (containing 29 ESs) resulted in an ES of 1.39 (1.07, 1.72; P<0.001), 
representing a 10.4% increase in strength.  Analysis of 8 transdermal TRT studies (containing 33 
ESs) produced an ES of 0.26 (-0.19, 0.70; P=0.26), indicating transdermal TRT did not improve 
lower-extremity strength.   
Upper Extremity Strength 
 For upper-extremity strength, we integrated 12 transdermal and intramuscular TRT 
studies (containing 38 ESs) and obtained a pooled overall treatment ES of 1.13 (0.78,1.47; 
P<0.001), representing a 7.8% strength increase versus placebo (Table 4).  Separate analysis of 
the 6 intramuscular studies (containing 15 ESs) resulted in an ES of 1.37 (1.03, 1.70; P<0.001), 
representing a 12.9% increase in strength.  In comparison, separate analysis of 6 transdermal 
TRT studies (containing 23 ESs) produced an ES of 0.97 (0.50, 1.45; P<0.001), representing 
only a 4.5% strength improvement.  
Sensitivity Analysis 
 We conducted sensitivity analyses to ensure that RCTs containing multiple ESs for 
upper- and/or lower-extremity strength did not bias our outcomes.  Using the Mantel-Haenszel 
approach [26], ESs and percent improvements were similar to the primary/secondary strength 
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outcomes reported above, with intramuscular TRT being associated with the largest ES 
magnitudes and greatest percentage improvements for all strength outcomes (Table 5).  
Subgroup Analyses – Older Men 
 To evaluate the effects of TRT in older men, we conducted sub-analyses of RCTs 
that limited enrollment to men ≥60 years of age.  For FFM, we included 16 transdermal 
and intramuscular TRT studies (containing 18 ESs) and obtained a pooled overall 
treatment ES of 1.36 (95%CI: 0.88, 1.83; P<0.001, Figure 5), representing a 4.2% increase 
in FFM for TRT versus placebo (Table 6).  Sub-analysis of the 7 studies administering 
intramuscular TRT produced an ES of 1.84 (1.12, 2.55; P<0.001), representing a 7.3% 
FFM increase.  In comparison, sub-analysis of the 9 studies evaluating transdermal TRT 
produced an ES of 1.04 (0.41, 1.67; P<0.001), representing only a 1.7% increase in FFM.  
For total body strength, we integrated 14 transdermal and intramuscular TRT studies 
(containing 93 ESs) that reported lower-extremity (Figure 6) or upper-extremity strength 
measures (Figure 7) and obtained a pooled overall treatment ES of 0.90 (0.67, 1.14; 
P<0.001), representing a 6.1% increase in strength versus placebo.  The ESs and 
percentage increases for intramuscular and for transdermal TRT studies were similar to 
the primary strength outcomes reported above, with intramuscular TRT being associated 
with the largest ES magnitudes and greatest percent improvements (Table 6). 
DISCUSSION 
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The increasing prevalence of TRT [62] is likely to continue, as a result of the increasing 
geriatric population.  Previous meta-analyses of RCTs have reported that TRT positively 
influences health-related quality of life [63], bone mineral density (BMD) [64, 7], body 
composition [65, 66, 7, 6], sexual function and libido [67, 7], and several measures of metabolic 
health in men [65].  However, debate surrounds the potential utility of various TRT formulations 
in relation to promoting musculoskeletal integrity, muscular strength, and physical function in 
middle-aged and elderly men [9, 10].  For example, Corona et al reported that parenteral (i.e., 
intramuscular and transdermal) TRT collectively increased FFM, while oral TRT did not [65].  
Tracz et al also reported that intramuscular TRT increased lumbar spine BMD, while transdermal 
formulations did not [64].  Similarly, meta-analyses have reported that oral TRT [19] and 
transdermal formulations [68] increase cardiovascular risk, while intramuscular TRT did not.  
These findings indicate that several risks and benefits associated with TRT may depend largely 
upon administration route [10].  The present meta-analysis was designed to supplement prior 
knowledge surrounding the effects of TRT on FFM and muscle strength in middle-aged and 
elderly men, and to determine the extent to which intramuscular and transdermal TRT 
administration routes effect these outcomes.  Our primary findings indicate that TRT increased 
total body FFM and total body strength when intramuscular and transdermal TRT routes were 
examined collectively and separately versus respective placebos.  Improvements in upper-
extremity and lower-extremity strength were also observed when TRT administration routes 
were collectively analyzed.  However, when evaluated separately, only intramuscular TRT 
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increased lower-extremity strength, with transdermal routes producing no improvement versus 
placebo.  Interestingly, for all outcomes assessed, the ESs for intramuscular TRT were larger and 
the percentage improvements were 3-5 times greater than that of transdermal TRT, supporting 
the contention that intramuscular TRT produces greater muscular benefit than transdermal 
administration.  Similar results persisted when we evaluated RCTs that limited enrollment 
to men ≥60 years of age, which is the age-range most likely to experience hypogonadism [1], 
indicating that intramuscular TRT is an effective means to improve FFM and muscle 
strength in older men. 
Comparison with Other Systematic Reviews - FFM 
It is generally accepted that TRT increases FFM in middle-aged and elderly men [9]; 
although, the magnitude of this effect may vary dramatically by administration route [10].  
Indeed, previous meta-analyses reported that TRT increased FFM from 1.6 kg (95%CI: 0.6, 2.6) 
[7] to 3.59 kg (2.38, 4.81) [6] when all administration routes were collectively assessed, a finding 
that is confirmed with our meta-analysis.  Herein, we expand upon these studies by separately 
evaluating the effects of intramuscular and transdermal TRT on FFM and demonstrate a much 
larger magnitude of increase occurs with intramuscular TRT.  Specifically, an apparent 
difference in percent change from baseline existed among administration routes, with a 5.7% 
increase in FFM resulting from intramuscular TRT and only a 1.7% increase resulting from 
transdermal formulations.  From a clinical perspective and as an example, this implies that a 90 
kg male would experience a 5.1 kg FFM increase with intramuscular TRT, as compared to a 1.5 
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kg FFM increase with transdermal formulations, providing further evidence for the potential 
utility of intramuscular TRT as means to prevent or reverse sarcopenia and frailty in 
hypogonadal men [10].  However, our data should be interpreted cautiously given that 1) 
DXA was used to evaluate FFM in most RCTs included in our meta-analysis (see Table 2) 
and 2) intra- and extra-cellular water are inherently included as components of FFM 
assessed via DXA [69].  In this regard, TRT increases extra-cellular water by ~2 kg in 
hypogonadal men [70] and peripheral edema has been observed in small fraction of older 
men receiving TRT [56].  Other musculoskeletal imaging technologies (e.g., computed 
tomography, magnetic resonance imaging, or ultrasound) are considered a somewhat more 
reliable means to directly assess muscle mass because they are not as heavily influenced by 
extra-cellular fluid fluctuations [71, 72], although, few RCTs have utilized these imaging 
modalities to assess muscular changes resulting from TRT.  Regardless, intramuscular 
TRT has been shown to increase muscle fiber cross-sectional area in older men, especially 
when administered at higher doses [73], demonstrating that testosterone produces direct 
myotrophic effects independent of fluid change.  
Several key differences also exist between our study and previous meta-analyses.  For 
example, other meta-analyses assessing FFM included oral TRT (e.g., testosterone undecanoate, 
oxandrolone, and/or oxymetholone) or dihydrotestosterone formulations [65, 66, 7, 6].  We 
excluded RCTs administering dihydrotestosterone or oral TRT because: 1) from a clinical 
standpoint, these formulations are not commonly prescribed in the US [62], 2) Corona et al 
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recently reported that oral TRT did not increase FFM when evaluated separately from other 
parenteral TRT formulations [65], and 3) several RCTs have demonstrated that 5α-reduction of 
testosterone to dihydrotestosterone does not mediate improvements in FFM or muscular strength 
resulting from TRT [16, 17, 74].  Interestingly, our previous meta-analysis reported that 
transdermal TRT elevated circulating dihydrotestosterone to a greater magnitude than 
intramuscular formulations [10], likely due to the relatively higher 5α-reductase expression in 
skin versus skeletal muscle [75]; although, the clinical ramifications of these differing 
dihydrotestosterone elevations remain unknown.   
Comparison with Other Systematic Reviews - Strength 
Our finding that muscular strength improvements varied in middle-aged and elderly men 
based on TRT administration route provides evidence that accounts for the contrasting 
observations reported in several previous RCTs and meta-analyses [10].  For example, some 
RCTs reported that TRT produced pronounced FFM and strength improvements [15, 49], while 
others reported very minimal changes in comparison with placebo [12, 11, 13, 14].  Conflicting 
results are also present among meta-analyses, with Ottenbacher et al [8] reporting that TRT 
increased upper- and lower-extremity strength in middle-aged and elderly men and Isidori et al 
[7] reporting no improvement in knee extension, leg extension, knee flexion, or handgrip 
strength.  In our meta-analysis, muscle strength was quantified as change from baseline, 
compared with respective placebo, and was comprised of three strength domains: (1) upper-
extremity, (2) lower-extremity, and (3) total body.  Across all strength domains, intramuscular 
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TRT yielded higher ESs and percent changes compared to transdermal TRT.  Specifically, 
within the entire cohort, intramuscular TRT produced a very large and significant ES (ES: 
1.39, 10.4% improvement) for lower-extremity strength, while transdermal TRT did not 
significantly improve this measure.  Likewise, we observed a larger ES for upper-extremity 
strength for intramuscular TRT (ES: 1.37, 12.9% improvement) than for transdermal TRT (ES: 
0.97, 4.5% improvement).  Similarly, when upper- and lower-extremity strength measures were 
combined (i.e., total body strength), we observed a very large ES for intramuscular TRT (ES: 
1.39, 11.2% improvement) and only a medium ES for transdermal TRT (ES: 0.55, 2.1% 
improvement).  The most likely explanation for the differing strength outcomes reported in our 
meta-analysis and that of Isidori et al [7] are that we included more data points, despite limiting 
our selection criteria to double-blind, placebo-controlled RCTs, which was possible because we 
pooled upper- and lower-extremity strength assessments.  Indeed, our results corroborate and 
update the findings of Ottenbacher et al [8], which is the only other meta-analysis of placebo-
controlled RCTs that evaluated muscle strength responses in men receiving TRT, with the 
following caveats: (1) we evaluated total body FFM and report a larger magnitude of 
improvement with intramuscular TRT, providing a physiologic rationale for the larger strength 
improvements occurring with this administration route; (2) we did not include studies that 
administered dihydrotestosterone or oral TRT; and (3) we report that intramuscular TRT 
produced similar improvements for upper- and lower-extremity strength, while Ottenbacher et al 
reported a higher ES for lower-extremity than for upper-extremity strength, which is likely 
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explained by the larger number of ESs reported in our analysis (100 vs 38).  In addition, we 
evaluated RCTs that limited enrollment to men ≥60 years of age and observed that the 
magnitude of strength improvements were similar to that occurring in the entire cohort, 
indicating the effects of intramuscular TRT on muscle strength persist in older men. 
Clinical Relevance 
The Endocrine Society recommends that the therapeutic target for adult men with 
classical androgen deficiency is the mid-normal range for healthy, young men (i.e., 400-750 
ng/dL), with values assessed one-week post-injection for intramuscular TRT or on the day of 
administration for transdermal formulations [9].  To accomplish this, transdermal patch-based 
TRT preparations typically contain relatively low testosterone doses (35-70 mg T/week), while 
transdermal gel-based TRT formulations contain much higher doses (350-1000 mg T/week) due 
to low drug absorption [76, 77].  Regardless, transdermal patch- and gel-based TRT 
formulations both maintain circulating testosterone in the physiologic range [19].  In 
comparison, intramuscular TRT typically delivers an intermediate testosterone dose (75-100 
mg/week) [9], with differing pharmacokinetics than transdermal formulations, which results in 
substantially higher circulating testosterone for several days after administration and values that 
gradually decline into the physiologic range thereafter [18].  It is likely that the larger 
increase in circulating testosterone resulting from intramuscular TRT at least partially explains 
the greater FFM and strength improvements occurring with the intramuscular administration 
route, as TRT-induced improvements in muscle fiber cross-sectional area [73] and muscle 
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strength are dose-dependent in older men [21].  The clinical ramifications of this apparent 
dose-response effect seem clear, given that muscle quality and physical function are strongly 
associated [78] and that muscle strength, particularly in the lower-extremities, is independently 
associated with reduced mobility disability [79] and less functional decline in elderly men [80].   
Limitations 
No RCT to-date has directly compared muscular responses to different TRT 
administration routes.  Our meta-analysis was designed to compare intramuscular and 
transdermal TRT versus respective placebos, and to infer differences among administration 
routes based on ES and percent change from baseline.  We believe this approach is an 
appropriate surrogate to a more direct dose-response analysis because 1) intramuscular 
TRT produces much higher circulating testosterone, on average, than transdermal TRT 
formulations [19, 18], 2) the different TRT formulations that we evaluated have vastly 
different testosterone absorption profiles and pharmacokinetics [18, 20], which limits a 
direct dose-response comparison, and 3) several RCTs included in our meta-analysis 
titrated TRT dose at the individual patient level [30, 15, 38, 13, 11, 50, 14, 55], for which 
TRT dose and circulating testosterone data are not readily available.  In addition, we did not 
selectively evaluate RCTs that enrolled men with hypogonadism because this would dramatically 
reduce the number of qualifying studies.  However, the TRT and placebo groups from 7 
intramuscular RCTs and 6 transdermal RCTs included in our analysis exhibited serum 
testosterone concentrations within the hypogonadal range.  As such, future RCTs comparing 
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muscular responses to intramuscular and transdermal TRT formulations in hypogonadal 
men are warranted.   
Conclusion 
In summary, our meta-analysis of double-blind, placebo-controlled RCTs revealed that 
TRT increased FFM, total body strength, and upper- and lower-extremity strength when 
transdermal and intramuscular administration routes were evaluated collectively.  Separate 
analysis of transdermal and intramuscular TRT versus respective placebos demonstrated that 
intramuscular TRT leads to larger ESs and 3-5 times greater percent improvement for all strength 
and FFM outcomes assessed.  This effect was most pronounced for lower-extremity strength, 
which increased >10% with intramuscular TRT and did not improve with transdermal 
formulations.  Similar FFM and muscle strength responses were observed when selectively 
evaluating RCTs that limited enrollment to men ≥60 years of age.  These results suggest that 
intramuscular TRT is more effective than transdermal TRT in terms of preventing sarcopenia 
and improving muscle strength and physical function in middle-aged and elderly men.   
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FIGURE LEGEND 
Figure 1. Selection process for double-blind, placebo-controlled randomized clinical trials 
(RCTs) assessing effects of testosterone replacement therapy (TRT) on fat-free mass (FFM) 
and/or muscle strength outcomes in middle-aged and older men.  
 
Figure 2. Forest plot for fat-free mass (FFM) data derived from placebo-controlled randomized 
clinical trials (RCTs) of middle-aged and older men.  Values are the individual and pooled 
effect sizes (ESs) listed by testosterone replacement therapy (TRT) administration route. 
 
Figure 3. Forest plots for lower-extremity muscle strength data derived from placebo-controlled 
randomized clinical trials (RCTs) of middle-aged and older men.  Values are the individual and 
pooled effect sizes (ESs) listed by testosterone replacement therapy (TRT) administration route. 
 
Figure 4. Forest plots for upper-extremity muscle strength data derived from placebo-controlled 
randomized clinical trials (RCTs) of middle-aged and older men.  Values are the individual and 
pooled effect sizes (ESs) listed by testosterone replacement therapy (TRT) administration route. 
 
Figure 5. Forest plot for fat-free mass (FFM) data derived from placebo-controlled 
randomized clinical trials (RCTs) that limited enrollment to men ≥60 years of age.  Values 
are the individual and pooled effect sizes (ESs) listed by testosterone replacement therapy 
(TRT) administration route. 
This article is protected by copyright. All rights reserved.
 
 
23 
 
 
Figure 6. Forest plot for lower-extremity muscle strength data derived from placebo-
controlled randomized clinical trials (RCTs) that limited enrollment to men ≥60 years of 
age.  Values are the individual and pooled effect sizes (ESs) listed by testosterone 
replacement therapy (TRT) administration route. 
 
Figure 7. Forest plot for upper-extremity muscle strength data derived from placebo-
controlled randomized clinical trials (RCTs) that limited enrollment to men ≥60 years of 
age.  Values are the individual and pooled effect sizes (ESs) listed by testosterone 
replacement therapy (TRT) administration route.  
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Figure 1. Selection process for double-blind, placebo-controlled randomized clinical trials 
(RCTs) assessing effects of testosterone replacement therapy (TRT) on fat-free mass (FFM) 
and/or muscle strength outcomes in middle-aged and older men.  
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aThe discrepancy among total number of qualifying RCTs (n=41) and those qualifying for FFM 
(n=35) or strength analyses (n=23) stems from RCTs (n=17) that qualified for both analyses.   
bRCTs (n=7) were excluded because data were not provided in a format that could be analyzed 
with our a priori statistical design, of which, n=2 qualified for both FFM and strength analyses.  
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Figure 2. Forest plot for fat-free mass (FFM) data derived from placebo-controlled randomized 
clinical trials (RCTs) of middle-aged and older men.  Values are the individual and pooled 
effect sizes (ESs) listed by testosterone replacement therapy (TRT) administration route. 
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Figure 3. Forest plots for lower-extremity muscle strength data derived from placebo-
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controlled randomized clinical trials (RCTs) of middle-aged and older men.  Values are the 
individual and pooled effect sizes (ESs) listed by testosterone replacement therapy (TRT) 
administration route. 
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Figure 4. Forest plots for upper-extremity muscle strength data derived from placebo-
controlled randomized clinical trials (RCTs) of middle-aged and older men.  Values are the 
individual and pooled effect sizes (ESs) listed by testosterone replacement therapy (TRT) 
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administration route. 
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Figure 5. Forest plot for fat-free mass (FFM) data derived from placebo-controlled 
randomized clinical trials (RCTs) that limited enrollment to men ≥60 years of age.  
Values are the individual and pooled effect sizes (ESs) listed by testosterone replacement 
therapy (TRT) administration route. 
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Figure 6. Forest plot for lower-extremity muscle strength data derived from placebo-
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controlled randomized clinical trials (RCTs) that limited enrollment to men ≥60 years of 
age.  Values are the individual and pooled effect sizes (ESs) listed by testosterone 
replacement therapy (TRT) administration route. 
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Figure 7. Forest plot for upper-extremity muscle strength data derived from placebo-
controlled randomized clinical trials (RCTs) that limited enrollment to men ≥60 years of 
age.  Values are the individual and pooled effect sizes (ESs) listed by testosterone 
This article is protected by copyright. All rights reserved.
 
 
48 
 
replacement therapy (TRT) administration route. 
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Table 1. Quality assessment for double-blind placebo-controlled randomized clinical trials 
(RCTs) evaluated, using the Delphi criteria.a 
Article Treatment 
Allocation 
Concealed 
Groups 
Similar at 
Baselineb 
Estimate & 
Variance 
Presented 
Agledahl et al, 2008 [28]  N/R Yes Yes 
Allan et al, 2008 [29] Yes N/R Yes 
Basaria et al, 2010 [56] Yes Yes / N/Rc Nod 
Behre et al, 2012 [30] Yes Yes Yes 
Blackman et al, 2002 [31] Yes Yes / Noe Yes 
Borst et al, 2014 [16] Yes Yes Yes 
Brockenbrough et al, 2006 [32] Yes N/R Yes 
Caminiti et al, 2009 [33] Yes Yes Yes 
Casaburi et al, 2004 [34] N/R Yes / N/Rc Yes 
Clague et al, 1999 [35] Yes Yes Yes 
Crawford et al, 2003 [36] N/R Yes / N/Rf Yesg 
Del Fabbro et al, 2013 [57] Yes Yes Nod 
Dhindsa et al, 2016 [37] N/R Yes Yes 
Dias et al, 2016 [58] Yes Yes Nod 
Ferrando et al, 2002 [15] N/R Yes Yesg 
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Frederiksen et al, 2012 [38] Yes Yes Yes 
Gianatti et al, 2014 [39] Yes Yes Yesg 
Giannoulis et al, 2006 [40] N/R Yes Yes 
Hildreth et al, 2013 [13] Yes Yes Yesg 
Hoyos et al, 2012 [41] Yes Yes Yesg 
Katznelson et al, 2006 [42] N/R Yes Yes 
Kenny et al, 2001 [44] Yes Yes Yes 
Kenny et al, 2010 [43] Yes Yes Yes 
Kvorning et al, 2013 [45] Yes N/R Yesg 
Magnussen et al, 2016 [46] Yes Yes Yes 
Malkin et al, 2005 [59] N/R Yes Nod 
Marin et al, 1993 [47] N/R Yes Yes 
Merza et al, 2006 [48] Yes Yes Yes 
Nair et al, 2006 [12] Yes Yes Nod 
Page et al, 2005 [17] Yes Yes Yesg 
Sheffield-Moore et al, 2011 [49] N/R Yes Yesg 
Sih et al, 1997 [60] N/R N/R Nod 
Sinclair et al, 2016 [61] Yes Yes Nod 
Snyder et al, 1999 [11] Yes Yes Yes 
Srinivas-Shankar et al, 2010 [50] Yes Yes Yes 
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Steidle et al, 2003 [51] N/R Yes Yes 
Storer et al, 2017 [14] Yes Yes Yesg 
Svartberg et al, 2004 [52] N/R Yes Yesg 
Svartberg et al, 2008 [53] N/R Yes Yes 
Tenover et al, 1992 [54] N/R Yes Yes 
Travison et al, 2011 [55] Yes N/R Yes 
N/R = not reported.  aAll RCTs were randomized, with the investigators, providers, and 
subjects blinded to treatment allocation, and eligibility criteria were specified.   bBaseline 
characteristics assessed were fat-free mass (FFM) and muscle strength.  cN/R for FFM.  
dEstimate and variance were not reported in the necessary format for statistical analysis in the 
original article and data were not provide via author query, study was excluded from meta-
analysis. eDifference in FFM between TRT and placebo groups at baseline.  fN/R for strength.  
gEstimate and variance were not provided in the necessary format for statistical analysis in the 
original article, these data were obtained via author query. 
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Table 2. Characteristics of placebo-controlled randomized clinical trials (RCTs) that were included in meta-analyses. 
Article Age 
(years) 
Baseline TRT Characteristics Duration 
(months) 
Reported Outcomes 
Ta N Route Mode Dose FFM Strength 
Agledahl et al, 2008 [28]  T: 68.9 
P: 69.3 
T: 245 
P: 237 
T: 13 
P: 13 
i.m. TU 1000 mg 
5x/year 
12 DEXA N/A 
Allan et al, 2008 [29]  T: 62.1 
P: 64.5 
T: 392 
P: 418 
T: 31 
P: 31 
trans T patch 5 mg/day 12 DEXA N/A 
Behre et al, 2012 [30]   T: 61.9 
P: 62.1 
T: 300 
P: 306 
T: 183 
P: 179 
trans T gel 50-100 mg/ 
day 
6 DEXA N/A 
Blackman et al, 2002 [31]  T: 70.0 
P: 70.0 
T: 409 
P: 392 
T: 21 
P: 17 
i.m. TE 100 mg/ 
2 weeks 
6 DEXA N/A 
Borst et al, 2014 [16]   T: 69.2 
P: 70.8 
T: 245 
P: 264 
T: 14 
P: 16 
i.m. TE 125 mg/ 
week 
12 DEXA L, U 
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Brockenbrough et al, 2006 [32]   T: 58.9 
P: 53.0 
T: 219 
P: 202 
T: 19 
P: 21 
trans T gel 100 mg/day 6 DEXA N/A 
Caminiti et al, 2009 [33]  T: 71 
P: 69 
T: 230 
P: 210 
T: 35 
P: 35 
i.m. TU 1000 mg/  
6 weeks 
3 N/A L 
Casaburi et al, 2004 [34]  T: 66.6 
P: 67.7 
T: 302 
P: 302 
T: 12 
P: 12 
i.m. TE 100 mg/ 
week 
2.5 DEXA L 
Clague et al, 1999 [35]  T: 68.1 
P: 65.3 
T: 326 
P: 335 
T: 7 
P: 7 
i.m. TE 200 mg/  
2 weeks 
3 N/A L, U 
Crawford et al, 2003 [36]  T: 58.7 
P: 59.9 
T: 398 
P: 453 
T: 18 
P: 16 
i.m. Mixed 200 mg/  
2 weeks 
12 DEXA L 
Dhindsa et al, 2016 [37]  T: 54.7 
P: 54.5 
T: 252 
P: 252 
T: 22 
P: 22 
i.m. TC 250 mg/  
2 weeks 
6 DEXA N/A 
Ferrando et al, 2012 [15]  T: 68 T: N/R T: 7 i.m. TE 100-400 mg/ 6 DEXA L, U 
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P: 67 P: N/R P: 5 2 weeks  
Frederiksen et al, 2011 [38]  T: 68 
P: 67 
T: 361 
P: 366 
T: 23 
P: 23 
trans T gel 50-100 mg/ 
day 
6 DEXA N/A 
Gianatti et al, 2014 [39]  T: 62 
P: 62 
T: 251 
P: 245 
T: 45 
P: 43 
i.m. TU 1000 mg 
4x/40 weeks 
9.25 DEXA N/A 
Giannoulis et al, 2006 [40]  T: 70.3 
P: 69.5 
T: 498 
P: 432 
T: 23 
P: 20 
trans T patch 5 mg/day 6 DEXA L, U 
Hildreth et al, 2013 [13]  T: 66.5 
P: 66.5 
T: 298b 
P: 294 
T: 55 
P: 28 
trans T gel 25-100 mg/ 
day 
12 DEXA L, U 
Hoyos et al, 2012 [41]  T: 48 
P: 49 
T: 381 
P: 387 
T: 33 
P: 34 
i.m. TU 1000 mg/  
6 weeks 
4.5 DEXA N/A 
Katznelson et al, 2006 [42]  T: 72 
P: 72 
T: 392 
P: 421 
T: 17 
P: 17 
trans T patch 5 mg/day 3 DEXA N/A 
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Kenny et al, 2001 [44]  T: 76 
P: 75 
T: 389 
P: 389 
T: 24 
P: 20 
trans T patch 5 mg/day 12 DEXA L 
Kenny et al, 2010 [43]  T: 77.9 
P: 76.3 
T: 380 
P: 418 
T: 69 
P: 62 
trans T gel 5 mg/day 12 DEXA L, U 
Kvorning et al, 2013 [45]  T: 66.6 
P: 67.8 
T: 147c 
P: 133c 
T: 22 
P: 23 
trans T gel 50 mg/  
day 
6 
 
N/A L 
Magnussen et al, 2016 [46]  T: 61 
P: 59 
T: 205 
P: 271 
T: 22 
P: 21 
trans T gel 50 mg/day 6 DEXA N/A 
Marin et al, 1993 [47]  T: 56.7 
P: 58.5 
T: 436 
P: 447 
T: 7 
P: 7 
trans T gel 125 mg/day 9 40K  N/A 
Merza et al, 2005 [48]  T: 63.0 
P: 59.7 
T: 242 
P: 216 
T: 20 
P: 19 
trans T patch 5 mg/day 6 DEXA N/A 
Page et al, 2005 [17]  T: 71 T: 286 T: 24 i.m. TE 200 mg/ 36 DEXA L, U 
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P: 71 P: 303 P: 24 2 weeks 
Sheffield-Moore et al, 2011 [49] T: 73 
P: 65 
T: 349† 
P: 344 
T: 16 
P: 8 
i.m. TE 100 mg/ 
week 
5 DEXA L, U 
Snyder et al, 1999 [11]  T: 73.1 
P: 73.0 
T: 367 
P: 369 
T: 54 
P: 54 
trans T patch 4-6 mg/day 36 DEXA L, U 
Srinivas-Shankar et al, 2010 [50]  T: 73.7 
P: 73.9 
T: 317 
P: 314 
T: 130 
P: 132 
trans T gel 25-75 mg/ 
day 
6 DEXA L, U 
Steidle et al, 2003 [51] T: 58.4 
P: 56.8 
T: 234† 
P: 228 
T: 205 
P: 99 
trans T gel 50-100 mg/ 
day 
3 DEXA N/A 
Storer et al, 2017 [14]  T: 66.6 
P: 68.0 
T: 307 
P: 302 
T: 135 
P: 121 
trans T gel 50-100 mg/ 
day 
36 DEXA L, U 
Svartberg et al, 2004 [52]  T: 64.5 
P: 67.5 
T: 591 
P: 623 
T: 15 
P: 14 
i.m. TE 250 mg/ 
4 weeks 
6 DEXA N/A 
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Svartberg et al, 2008 [53]  T: 69 
P: 69 
T: 242 
P: 237 
T: 17 
P: 18 
i.m. TU 1000 mg 
5x/year 
12 DEXA L, U 
Tenover et al, 1992 [54]  T: 67.5 
P: 67.5 
T: 335 
P: 335 
T: 13 
P: 13 
i.m. TE 100 mg/ 
week 
3 Hydro N/A 
Travison et al, 2011 [55]  T: 73.8 
P: 73.9 
T: 251 
P: 231 
T: 69 
P: 69 
trans T gel 50-150 mg/ 
day 
6 DEXA N/A 
aTestosterone (T) concentrations are ng/dL, rounded to the nearest whole number.  bIndicates average T concentration from all groups 
receiving TRT. cIndicates bioavailable T concentration, total T was not reported. N = number per group; P = placebo-treated group; 
i.m. = intramuscular; trans = transdermal; Mixed = mixed injectable esters; TC = testosterone cypionate; TE = testosterone enanthate; 
TP = testosterone proprionate; TU = testosterone undecanoate; T gel = testosterone gel; T patch = testosterone patch; FFM = fat-free 
mass; DEXA = dual x-ray absorptiometry; 40K = whole-body potassium-40 measurement; Hydro = hydrostatic weighing; L = lower-
extremity; U = upper-extremity; N/A = not assessed; N/R = not reported.   
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Table 3. Characteristics of placebo-controlled randomized clinical trials (RCTs) that were excluded from meta-analyses due to 
inability to acquire data in the format necessary for our a priori statistical design. 
Article Age 
(years) 
Baseline  TRT  Duration 
(months) 
Reported Outcomes 
Ta N Route Mode Dose FFM Strength 
Basaria et al, 2010 [56] T: 74 
P: 74 
T: 250 
P: 236 
T: 106 
P: 103 
trans T gel 100-150 mg/ 
day 
6 DEXAb L,U 
Del Fabbro et al, 2013 [57] T: 57 
P: 63 
T: N/R 
P: N/R 
T: 16 
P: 13 
i.m. TE 150-200 mg/ 
2 weeks 
2.4 DEXA N/A 
Dias et al, 2016 [58] T: 72 
P: 72 
T: 300 
P: 304 
T: 13 
P: 13 
trans T gel 50 mg/day 12 DEXA N/A 
Malkin et al, 2006 [59] T: 63.1 
P: 64.9 
T: 401 
P: 349 
T: 37 
P: 39 
trans T patch 5 mg/day 12 N/A U 
Nair et al, 2006 [12] T: 66.2 T: 357 T: 27 trans T patch 5 mg/day 24 DEXA L,U 
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P: 67.1 P: 398 P: 31 
Sih et al, 1997 [60] T: 65 
P: 68 
T: 233 
P: 294 
T: 17 
P: 15 
i.m. TC 200 mg/ 
2 weeks 
12 N/A U 
Sinclair et al, 2016 [61]  T: 55.5 
P: 54.0 
T: 267 
P: 262 
T: 50 
P: 51 
i.m. TU 1000 mg/  
52 weeks 
12 DEXA U 
aTestosterone (T) concentrations are ng/dL, rounded to the nearest whole number. bData were included in meta-analysis, obtained 
from reference [55]; N = number per group; P = placebo; i.m. = intramuscular; trans = transdermal; T gel = testosterone gel; T 
patch = testosterone patch; TC = testosterone cypionate; TE = testosterone enanthate; TU = testosterone undecanoate; FFM = fat-
free mass; DEXA = dual x-ray absorptiometry; L = lower-extremity; U = upper-extremity; N/A = not assessed; N/R = not reported 
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Table 4. Effect sizes and percent improvement for total body fat-free mass (FFM) and muscle strength outcomes 
from placebo-controlled randomized clinical trials (RCTs) of middle-aged and older men. 
TRT Route G-Index 
(N) 
Sample Size 
(TRT, Placebo) 
Effect 
Size 
SE 95% CI p-value Improvement 
(%) 
FAT-FREE MASS 
    Overall 34 (1213, 1168) 1.200 0.150 (0.910, 1.490) <0.001 3.4 
    Intramuscular 15 (242, 230) 1.490 0.180 (1.130, 1.840) <0.001 5.7 
    Transdermal 19 (971, 938) 0.980 0.210 (0.580, 1.390) <0.001 1.7 
TOTAL BODY STRENGTH 
    Overall 100 (2572, 2523) 0.900 0.120 (0.670, 1.140) <0.001 6.1 
    Intramuscular 44 (561, 580) 1.390 0.120 (1.150, 1.630) <0.001 11.2 
    Transdermal 56 (2011, 1943) 0.550 0.170 (0.220, 0.880) <0.001 2.1 
LOWER-EXTREMITY STRENGTH 
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    Overall 62 (1717, 1668) 0.770 0.160 (0.450, 1.080) <0.001 5.0 
    Intramuscular 29 (402, 412) 1.390 0.170 (1.070, 1.720) <0.001 10.4 
    Transdermal 33 (1315, 1256) 0.260 0.230 (-0.190, 0.700) 0.260 0.3 
UPPER-EXTREMITY STRENGTH 
    Overall 38 (855, 855) 1.130 0.180 (0.780, 1.470) <0.001 7.8 
    Intramuscular 15 (159, 168) 1.370 0.170 (1.030, 1.700) <0.001 12.9 
    Transdermal 23 (696, 687) 0.970 0.240 (0.500, 1.450) <0.001 4.5 
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Table 5. Effect sizes and percent improvement for sensitivity analyses of muscle strength outcomes from placebo-
controlled randomized clinical trials (RCTs) of middle-aged and older men.   
Route G-Index 
(N) 
Sample Size 
(TRT, Placebo) 
Effect 
Sizea 
SE 95% CI p-value Improvement 
(%) 
TOTAL BODY STRENGTH 
    Overall 35 (1175, 1126) 1.120 0.190 (0.750, 1.490) <0.001 6.9 
    Intramuscular 17 (230, 244) 1.510 0.210 (1.090, 1.930) <0.001 11.3 
    Transdermal 18 (945, 882) 0.790 0.270 (0.270, 1.320) <0.001 2.7 
LOWER-EXTREMITY STRENGTH 
    Overall 21 (724, 695) 1.090 0.260 (0.580, 1.600) <0.001 6.3 
    Intramuscular 10 (154, 161) 1.630 0.310 (1.030, 2.230) <0.001 10.7 
    Transdermal 11 (570, 534) 0.650 0.360 (-0.060, 1.360) 0.070 2.4 
UPPER-EXTREMITY STRENGTH 
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    Overall 14 (451, 431) 1.160 0.280 (0.610, 1.720) <0.001 7.7 
    Intramuscular 7 (76, 83) 1.310 0.260 (0.800, 1.810) <0.001 12.1 
    Transdermal 7 (375, 348) 1.020 0.430 (0.170, 1.870) 0.020 3.2 
aStrength measures with the same units of measurement from each study were averaged to form a single effect size.  
Sensitivity analysis was not performed for fat-free mass (FFM) because all data points represented individual 
groups with identical units of measurement. 
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Table 6. Sub-analyses effect sizes and percent improvement for total body fat-free mass (FFM) and muscle 
strength outcomes from randomized clinical trials (RCTs) limiting enrollment to men ≥60 years of age.   
TRT Route G-Index 
(N) 
Sample Size 
(TRT, Placebo) 
Effect 
Size 
SE 95% CI p-value Improvement 
(%) 
FAT-FREE MASS 
    Overall 18 (574, 555) 1.360 0.240 (0.880, 1.830) <0.001 4.2 
    Intramuscular 8 (97, 99) 1.840 0.360 (1.120, 2.550) <0.001 7.3 
    Transdermal 10 (477, 456) 1.040 0.320 (0.410, 1.670) <0.001 1.7 
TOTAL BODY STRENGTH 
    Overall 93 (2382, 2355) 0.860 0.120 (0.620, 1.110) <0.001 5.9 
    Intramuscular 39 (477, 504) 1.330 0.130 (1.070, 1.590) <0.001 11.3 
    Transdermal 54 (1905, 1851) 0.550 0.170 (0.220, 0.880) <0.001 2.0 
LOWER-EXTREMITY STRENGTH 
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    Overall 56 (1580, 1546) 0.660 0.170 (0.320, 0.990) <0.001 4.5 
    Intramuscular 24 (318, 336) 1.300 0.190 (0.920, 1.670) <0.001 10.3 
    Transdermal 32 (1262, 1210) 0.210 0.230 (-0.240, 0.670) 0.360 0.1 
UPPER-EXTREMITY STRENGTH 
    Overall 37 (802, 809) 1.170 0.170 (0.840, 1.500) <0.001 8.1 
    Intramuscular 15 (159, 168) 1.370 0.170 (1.030, 1.700) <0.001 12.9 
    Transdermal 22 (643, 641) 1.040 0.240 (0.580, 1.500) <0.001 4.8 
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